Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab for neoplasms
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person
Why this status
20 Apr 2025: Trial registered, NCT06936748
20 Jun 2025: Trial started, NCT06936748
The trials
NCT06936748: SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors
State
Under way
Phase
Phase 2
People
30 planned
Started
20 Jun 2025
Primary completion
19 Jun 2028
Arms
Radiotherapy Combined with Immunotherapy
Results
None posted
20 Apr 2025: Trial registered
20 Jun 2025: Trial started
How the status changed
19 Nov 2026: First set: Phase 2 trial
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.